These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9401942)
1. Pharmacokinetics of intragastrically administered digoxin in rabbits with experimental bile duct obstruction. Wójcicki M; Drozdzik M; Sulikowski T; Gawronska-Szklarz B; Wójcicki J; Rózewicka L; Skowron J; Zielinski S; Musial HD; Zakrzewski J J Pharm Pharmacol; 1997 Nov; 49(11):1082-5. PubMed ID: 9401942 [TBL] [Abstract][Full Text] [Related]
2. [The effect of experimental extrahepatic cholestasis on absorption, distribution and elimination of digoxin]. Wójcicki M Ann Acad Med Stetin; 1996; 42():51-65. PubMed ID: 9199126 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravenously administered digoxin and histopathological picture in rabbits with experimental bile duct obstruction. Wójcicki M; Drozdzik M; Sulikowski T; Wójcicki J; Gawrońska-Szklarz B; Zieliński S; Rózewicka L Eur J Pharm Sci; 2000 Sep; 11(3):215-22. PubMed ID: 11042227 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction. Wójcicki J; Sulikowski T; Wójcicki M; Droździk M; Gawrońska-Szklarz B; Barcew-Wiszniewska B; Skowron J; Rózewicka L Br J Pharmacol; 1996 Jan; 117(1):1-4. PubMed ID: 8825335 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of lidocaine and its major metabolite- monoethylglycinexylidide (MEGX) in rabbits with experimental common bile duct obstruction. Wójcicki J; Sulikowski T; Wójcicki M; Droździk M; Gawrońska-Szklarz B; Barcew-Wiszniewska B; Skowron J; Rózewicka L; Gołdyn U Eur J Drug Metab Pharmacokinet; 1995; 20(2):119-23. PubMed ID: 8582436 [TBL] [Abstract][Full Text] [Related]
6. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563 [TBL] [Abstract][Full Text] [Related]
7. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. Tsutsumi K; Kotegawa T; Kuranari M; Otani Y; Morimoto T; Matsuki S; Nakano S J Clin Pharmacol; 2002 Oct; 42(10):1159-64. PubMed ID: 12362931 [TBL] [Abstract][Full Text] [Related]
8. Effect of troglitazone on steady-state pharmacokinetics of digoxin. Loi CM; Knowlton PW; Stern R; Randinitis EJ; Vassos AB; Koup JR; Sedman AJ J Clin Pharmacol; 1998 Feb; 38(2):178-83. PubMed ID: 9549650 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction of sparfloxacin and digoxin. Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539 [TBL] [Abstract][Full Text] [Related]
10. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. Awni WM; Hussein Z; Cavanaugh JH; Granneman GR; Dubé LM Clin Pharmacokinet; 1995; 29 Suppl 2():92-7. PubMed ID: 8620677 [TBL] [Abstract][Full Text] [Related]
11. Alterations in pentobarbital and meperidine pharmacokinetics induced by bile duct ligation in the rat. Knodell RG; Brooks DA; Allen RC; Kyner WT J Pharmacol Exp Ther; 1980 Dec; 215(3):619-25. PubMed ID: 7441521 [TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice. Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937 [TBL] [Abstract][Full Text] [Related]
13. Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. Miyazawa Y; Sato T; Kobayashi K; Akahori F; Suzuki T; Miyashita H Am J Vet Res; 1990 Apr; 51(4):605-10. PubMed ID: 2327624 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. Yukawa E; Suematu F; Yukawa M; Minemoto M; Ohdo S; Higuchi S; Goto Y; Aoyama T Clin Pharmacokinet; 2001; 40(10):773-81. PubMed ID: 11707062 [TBL] [Abstract][Full Text] [Related]
15. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500 [TBL] [Abstract][Full Text] [Related]
16. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants. Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Ragueneau I; Poirier JM; Radembino N; Sao AB; Funck-Brentano C; Jaillon P Br J Clin Pharmacol; 1999 Sep; 48(3):453-6. PubMed ID: 10510161 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Johne A; Brockmöller J; Bauer S; Maurer A; Langheinrich M; Roots I Clin Pharmacol Ther; 1999 Oct; 66(4):338-45. PubMed ID: 10546917 [TBL] [Abstract][Full Text] [Related]
19. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin? Cohen E; Almog S; Staruvin D; Garty M Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338 [TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. Kawahara M; Sakata A; Miyashita T; Tamai I; Tsuji A J Pharm Sci; 1999 Dec; 88(12):1281-7. PubMed ID: 10585223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]